Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age65+
SponsorKaiser Permanente
About this trial
This study will evaluate the relative vaccine effectiveness of quadrivalent adjuvanted inactivated influenza vaccine (aIIV4) versus quadrivalent high-dose inactivated influenza vaccine (HD-IIV4) in preventing polymerase chain reaction (PCR)-confirmed influenza and influenza-related outcomes in adults ≥65 years of age during the 2023/24, 2024/25, and 2026/27 influenza seasons. The study is an observational study conducted at Kaiser Permanente Northern California (KPNC), an integrated health care system in the United States.
Eligibility criteria
Qualifiers
Age ≥65 years at the time of influenza vaccination
KPNC member at the time of vaccination
Receive either aIIV4 or HD-IIV4 at a KPNC facility during the 2023/24 and/or 2024/25 influenza seasons
Disqualifiers
Age <65 years at the time of influenza vaccination
Received either aIIV4 or HD-IIV4 in the inpatient setting
Receive more than one influenza vaccination during a single season period (i.e., 2023/24 or 2024/25 influenza seasons)
Receive an influenza vaccination outside of KPNC
Trial design
Treatments tested in this trial
- Adjuvanted Quadrivalent Inactivated Influenza Vaccine (aIIV4)
- High-Dose Quadrivalent Inactivated Influenza Vaccine (HD-IIV4)
Treatment groups
1,500,000 Participants
are divided into 2 treatment groupsSponsors and collaborators
Kaiser Permanente
Lead sponsor
Seqirus
Collaborator
Source ClinicalTrials.gov